Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
6.69
+0.50 (8.08%)
At close: Feb 6, 2026, 4:00 PM EST
6.68
-0.01 (-0.15%)
After-hours: Feb 6, 2026, 7:05 PM EST
Unicycive Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
23
Market Cap
143.78M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 675.00K | -276.00K | -29.02% |
| Dec 31, 2022 | 951.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vaxart | 148.20M |
| Spero Therapeutics | 40.55M |
| Sangamo Therapeutics | 32.88M |
| Caribou Biosciences | 9.30M |
| Cibus | 3.79M |
| Rani Therapeutics Holdings | 1.20M |
UNCY News
- 4 days ago - Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit - GlobeNewsWire
- 9 days ago - Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile - Seeking Alpha
- 10 days ago - UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - GlobeNewsWire
- 10 days ago - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - GlobeNewsWire
- 5 weeks ago - Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) - GlobeNewsWire
- 2 months ago - Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf - Newsfile Corp
- 2 months ago - Unicycive Therapeutics to Participate in Upcoming Investor Events in December - GlobeNewsWire
- 3 months ago - Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire